There is always hope beyond what you take it for granted.
We're dedicated to improve womens health through science.
Science
Ovarian Cancer
High-grade serous epithelial ovarian cancer (HGSOC) is the leading cause of death from gynecologic malignancies and the fifth most common cause of cancer-related death in women in the United States. Given that one in three women are affected by poor ovarian health, there is a significant unmet need for effective treatments, especially for those diagnosed with ovarian cancer.
Akkadian Therapeutics is addressing this need with our lead p53 mutant reactivator, AKT-100. This compound has demonstrated robust activity as a single agent and in combination with PARP inhibitors in multiple preclinical assays. AKT-100 is currently in its early drug discovery stage.
Breast and Pancreatic Cancer
Breast cancer is the most commonly diagnosed cancer among women in the U.S., and recent studies indicate that pancreatic cancer rates are rising faster in women than in men. Our team at Akkadian is dedicated to staying at the forefront of research and technology to continually improve women's health in this evolving industry.
We are currently developing novel molecules, AKT-100 and AKT-106, which have demonstrated robust activity in preclinical assays and animal models across various breast cancer and pancreatic cancer cell lines. Both AKT-100 and AKT-106 are presently in the preclinical stage.
Preeclampsia
Preeclampsia is a serious complication that affects 5-7% of pregnancies globally. It is characterized by high maternal blood pressure, kidney dysfunction, and proteinuria, and can lead to eclampsia in severe cases. Currently, there is no therapy available to treat the underlying causes of PE. The most effective course of action is often premature delivery, which unfortunately carries risks of reduced newborn survival and long-lasting developmental impairment.
Akkadian Therapeutics is developing AKT-1005 as a potential therapy for PE. In both in vitro studies and an established rodent model of PE, AKT-1005 has demonstrated significant benefits, including the reversal of maternal hypertension, a reduction in markers of oxidative stress, and the prevention of kidney dysfunction. AKT-1005 is currently in its early preclinical stage.
Our Team
- Akkadian's team members and consultants are renowned international scholars and seasoned professionals in pharmaceutical drug development. This includes clinician-scientists, synthetic process chemists, analytical and formulation chemists, pharmacologists, toxicologists, metabolism specialists, pathologists, statisticians, and molecular & cell biologists. Collectively, we have hundreds of publications in top-tier journals such as Nature, J Exp Med, J Med Chem, Biology, Circulation, Gastroenterology, J Clinical Investigation, and PNAS.
- The founders of AKTX are accomplished scientists who have invented a series of oncology, CNS, and ocular drugs. They include internationally recognized experts on critical illness, with one authoring 175 peer-reviewed publications on free radical stress, reperfusion injury, and circulatory shock. Our leadership also consists of former executives and directors from pharmaceutical companies with 25 years of experience leading medicinal chemistry, basic research, pharmacology, quality assurance, regulatory affairs, GMP manufacturing, and clinical investigation.
Pipeline
